共查询到20条相似文献，搜索用时 21 毫秒
1.
马流感A/马/京防/74-1(H7N7)毒株HA基因的序列分析 总被引：6，自引：0，他引：6
流感病毒(Influenza Virus)根据血凝素(HA)和神经氨酸酶(NA)两种表面抗原蛋白分为不同的亚型,马流感I型(H7N7)和Ⅱ型(H3N8)是其中比较重要的两个亚型.本研究应用无特定病原体(SPF)鸡胚增殖马流感病毒A/马/京防/74-1(H7N7)毒株,TRIzol LS Reagent提取病毒RNA,RT-PCR扩增HA基因全片段,克隆到PMD18-T载体上,并进行了鉴定和序列测定.所获得的HA基因片段长1 727 bp,编码563个氨基酸残基.根据推导的氨基酸序列进行预测,有7个潜在的糖基化位点和16个半胱氨酸残基,通过序列分析推断,A/马/京防/74-1(H7N7)株病毒的HA来源于禽类,是一株通过基因重排出现的重组病毒. 相似文献
2.
It has been recommended that modern equine influenza vaccines should contain an A/equi-1 strain and A/equi-2 strains of the American and European-like subtype. We describe here the efficacy of a modern updated inactivated equine influenza-herpesvirus combination vaccine against challenge with a recent American-like isolate of equine influenza (A/equine-2/Kentucky/95 (H3N8). The vaccine contains inactivated Influenza strains A-equine-1/Prague'56, A-equine-2/Newmarket-1/'93 (American lineage) and A-equine-2/ Newmarket-2/93 (Eurasian lineage) and inactivated EHV-1 strain RacH and EHV-4 strain V2252. It is adjuvanted with alhydrogel and an immunostim. Horses were vaccinated at the start of the study and 4 weeks later. Four, six and eight weeks after the first vaccination high anti-influenza antibody titres were found in vaccinated horses, whereas at the start of the study all horses were seronegative. After the challenge, carried out at 8 weeks after the first vaccination, nasal swabs were taken, rectal temperatures were measured and clinical signs were monitored for 14 days. In contrast to unvaccinated control horses, vaccinated animals shed hardly any virus after challenge, and the appearance of clinical signs of influenza such as nasal discharge, coughing and fever were reduced in the vaccinated animals. Based on these observations, it was concluded that the vaccine protected against clinical signs of influenza and, more importantly, against virus excretion induced by an American-like challenge virus strain. In a second experiment the duration of the immunity induced by this vaccine was assessed serologically. Horses were vaccinated at the start of the study and 6 and 32 weeks later. Anti-influenza antibody titres were determined in bloodsamples taken at the first vaccination, and 2, 6, 8, 14, 19, 28, 32, 37, 41, 45 and 58 weeks after the first vaccination. Vaccinated horses had high anti-influenza antibody titres, above the level for clinical protection against influenza, against all strains present in the vaccine until 26 weeks after the third vaccination. 相似文献
3.
Effect of influenza A/equine/H3N8 virus isolate variation on the measurement of equine antibody responses. 
下载免费PDF全文
下载免费PDF全文 J R Bogdan P S Morley H G Townsend D M Haines 《Canadian journal of veterinary research》1993,57(2):126-130
This study has tested the effect of using homologous or heterologous equine influenza A virus isolates to evaluate serum antibody levels to influenza A virus in vaccinated and naturally-infected horses. In addition, the potential effect of antigenic selection of virus variants in egg versus tissue culture propagation systems was studied. Serum antibody levels in samples from horses recently infected with a local influenza A virus isolate (A/equine 2/Saskatoon/1/90) or recently vaccinated with a prototype isolate (A/equine 2/Miami/1/63) were assessed by hemagglutination inhibition and by single radial hemolysis using cell or egg-propagated A/equine 2/Saskatoon/1/90, A/equine 2/Miami/1/63 or A/equine 2/Fontainebleau/1/79. There were no significant differences in hemagglutination inhibition or single radial hemolysis antibody levels obtained with homologous or heterologous isolates or between viruses propagated in either eggs or cell culture. However there was a trend to higher titers in the hemagglutination inhibition assay when cell-propagated virus was used. These results suggest that antigenic variation in equine influenza A virus isolates and host-cell selection of antigenic variants during virus propagation may not be of sufficient magnitude to influence serological evaluation of antibody responses by hemagglutination inhibition or single radial hemolysis. 相似文献
4.
I. Donatelli M.R. Castrucci L. Campitelli A. Ruggieri L. Sidoli C. Buonavoglia 《Comparative immunology, microbiology and infectious diseases》1991,14(4):315-323
In Italy epizootics of equine influenza often occur, but no virus isolation has been reported since 1971. This paper describes the antigenic and biochemical characterization of two equine influenza viruses isolated in Italy from 1985 to 1989. The virus isolates were shown to differ antigenically from earlier strains of the same subtype, A/equine/Miami/1/63 (H3N8). Monoclonal antibody analysis showed that the haemagglutinins of these strains were serologically indistinguishable from A/equine/Fontainebleau/1/79, a variant of A/equine/Miami, never isolated in Italy before. One of the two virus isolates was obtained from a horse immunized with a bivalent inactivated influenza vaccine, not containing A/equine/Fontainebleau/79 antigens.
The vaccine failure underlines the importance of antigenic relatedness between currently circulating viruses and vaccine strains. Therefore, to improve the protection afforded by equine immunization, the vaccine composition should be decided according to the results of a virological surveillance activity, systematically conducted among horses. 相似文献
5.
Alternative vaccination against equine botulism (BoNT/C) 总被引：1，自引：0，他引：1
Frey J Eberle S Stahl C Mazuet C Popoff M Schatzmann E Gerber V Dungu B Straub R 《Equine veterinary journal》2007,39(6):516-520
REASON FOR PERFORMING STUDY: In Europe the incidence of botulism in horses has increased in the last decade due to the growing popularity of haylage feeding. Recombinant vaccines are safer and less expensive to produce and are generally better tolerated than toxoids. OBJECTIVES: To investigate whether the recombinant C-terminal half of the heavy chain of the botulinum neurotoxin C (Hc BoNT/C) in combination with an immunstimulatory adjuvant is an appropriate vaccine candidate for horses by testing its efficacy to induce neutralising antibodies and by comparing its immunogenic properties and adverse reactions to a commercial toxoid vaccine. Formation of oedema and local pain reactions were assessed. ELISA and Western blot assay against Hc BoNT/C and testing of neutralising antibody induction in a mouse protection assay were used to evaluate the immune response. RESULTS: With the recombinant vaccine, only minor local swelling with full recovery after 5 days was noted after brisket injections. The toxoid vaccine produced local, painful reactions with longer recovery periods of up to 2 weeks. Horses vaccinated with either vaccine induced neutralising antibodies after the second booster vaccination, while seroconversion on ELISA and Western blot to Hc BoNT/C was apparent after the first recombinant vaccination, and at various time points in the vaccination schedule in horses that received commercial toxoid vaccine. CONCLUSION: The recombinant vaccine showed fewer adverse reactions compared to the only commercially available vaccine but induced similar concentrations of neutralising antibodies. There was no correlation between the serological response to Hc BoNT/C and the neutralising capacity of serum. POTENTIAL RELEVANCE: Recombinant Hc BoNT/C is an appropriate vaccine candidate to stimulate production of neutralising antibodies against botulinum neurotoxin C in horses and creates only minor local reactions at the injection site. 相似文献
6.
Holmes MA Townsend HG Kohler AK Hussey S Breathnach C Barnett C Holland R Lunn DP 《Veterinary immunology and immunopathology》2006,111(1-2):67-80
Horses are commonly vaccinated to protect against pathogens which are responsible for diseases which are endemic within the general horse population, such as equine influenza virus (EIV) and equine herpesvirus-1 (EHV-1), and against a variety of diseases which are less common but which lead to greater morbidity and mortality, such as eastern equine encephalomyelitis virus (EEE) and tetanus. This study consisted of two trials which investigated the antigenicity of commercially available vaccines licensed in the USA to protect against EIV, EHV-1 respiratory disease, EHV-1 abortion, EEE and tetanus in horses. Trial I was conducted to compare serological responses to vaccines produced by three manufacturers against EIV, EHV-1 (respiratory disease), EEE, and tetanus given as multivalent preparations or as multiple vaccine courses. Trial II compared vaccines from two manufacturers licensed to protect against EHV-1 abortion, and measured EHV-1-specific interferon-gamma (IFN-gamma) mRNA production in addition to serological evidence of antigenicity. In Trial I significant differences were found between the antigenicity of different commercial vaccines that should be considered in product selection. It was difficult to identify vaccines that generate significant immune responses to respiratory viruses. The most dramatic differences in vaccine performance occurred in the case of the tetanus antigen. In Trial II both vaccines generated significant antibody responses and showed evidence of EHV-1-specific IFN-gamma mRNA responses. Overall there were wide variations in vaccine response, and the vaccines with the best responses were not produced by a single manufacturer. Differences in vaccine performance may have resulted from differences in antigen load and adjuvant formulation. 相似文献
7.
William P. Higgins DVM PhD James H. Gillespie VMD Douglas S. Robson PhD 《Journal of Equine Veterinary Science》1987,7(4)
Serum and colostrum were collected from 50 mares at parturition. Pre- and post-nursing serum samples were obtained from their foals. Bi-weekly serum samples were obtained from 25 of the foals for eight weeks. Hemagglutination-inhibiting (HAI) antibody titers to equine influenza viruses A1 and A2 (EIVA1 and EIVA2) and serum-neutralizing antibody titers to equine herpes virus 1 (EHV1) were measured in serum and colostrum samples. IgG levels in serum and colostrum were determined.No antibody was detected in any foal's pre-nursing serum sample. Foal post-nursing antibody and IgG levels were equivalent to those measured in their dam's sera (EHVA1 p=0.86; EHVA2 p=0.54; EHV1 p=0.91; IgG p=0.58). The half-life of maternally-acquired serum antibody in the foals was determined to be: EIVA1=28.88 days (26.4 to 31.7 days); EIVA2=29.1 days (26.7 to 32.1 days); EHV1=31.0 days (28.1 to 34.8 days). Colostrum contained antibody and IgG at levels ranging from 2 to 8 times higher (4.3 average) than those detected in the mare's serum. 相似文献
8.
K DYNON A VARRASSO N FICORILLI SA HOLLOWAY GH REUBEL F LI CA HARTLEY MJ STUDDERT HE DRUMMER 《Australian veterinary journal》2001,79(10):695-702
OBJECTIVE: To develop rapid (< 8 hour) tests using polymerase chain reaction (PCR) for the diagnosis of equine herpesvirus 3 (EHV3; equine coital exanthema virus), equine gammaherpesviruses 2 (EHV2) and EHV5, equine adenovirus 1 (EAdV1), EAdV2, equine arteritis virus (EAV), equine rhinitis A virus (ERAV; formerly equine rhinovirus 1) DESIGN: Either single round or second round (seminested) PCRs were developed and validated. METHODS: Oligonucleotide primers were designed that were specific for each virus, PCR conditions were defined and the specificity and sensitivity of the assays were determined. The application of the tests was validated using a number of independent virus isolates for most of the viruses studied. The PCRs were applied directly to clinical samples where samples were available. RESULTS: We developed a single round PCR for the diagnosis of EHV3, a seminested PCR for EHV2 and single round PCRs for EHV5, EAdV1, EAdV2 and RT-PCRs for EAV and ERAV. The PCR primer sets for each virus were designed and shown to be highly specific (did not amplify any recognised non-target template) and sensitive (detection of minimal amounts of virus) and, where multiple virus isolates were available all isolates were detected. CONCLUSION: The development and validation of a comprehensive panel of PCR diagnostic tests, predominantly for viruses causing equine respiratory disease, that can be completed within 8 hours from receipt of clinical samples, provides a major advance in the rapid diagnosis or exclusion diagnosis of these endemic equine virus diseases in Australia. 相似文献
9.
The aim of this study was to characterise CD4+T-cells in equines, as these cells are pivotal in establishing immune responses or regulating established ones. Peripheral blood mononuclear cells from a pony immunised with ovalbumin were cultured in vitro in the presence of the specific antigen and autologous antigen presenting cells. During the antigen starvation phase, cells were maintained on recombinant equine IL-2. After 35 days of culture, most of the cells were CD4+, CD8-and sIg-. Cells proliferated specifically in the presence of antigen, as tested on day 42 of culture. These cells were analysed by in-situ hybridisation to detect m RNA for IL-2 and IL-4, the presence of which suggested the existence of of Th1- and Th2-like cells. 相似文献
10.
11.
12.
13.
14.
15.
Contagious equine metritis 总被引：1，自引：0，他引：1
17.
20.
About ScienceDirect 《Journal of Equine Veterinary Science》2003,23(10):458-459